Nota Clínica

Intranasal disulfiram-induced encephalopathy: clinical and neuroimage findings

A. Matas-García, A. Téllez, S. Fernández, E. Salgado, P. Castro [REV NEUROL 2022;75:357-360] PMID: 36440748 DOI: https://doi.org/10.33588/rn.7511.2021415 OPEN ACCESS
Volumen 75 | Number 11 | Nº of views of the article 4.195 | Nº of PDF downloads 102 | Article publication date 01/12/2022
Icono-PDF-OFF Download PDF Castellano Icono-PDF-OFF Download PDF English Citation Search in PubMed
Share in: Facebook Twitter
Go to another issue
ABSTRACT Artículo en español English version
INTRODUCTION Disulfiram-induced-encephalopathy is a rare complication that has been well described in adults. Although it usually occurs in acute intoxication with high doses of disulfiram, late onset encephalopathy has also been reported. Some authors propose the inhibition of dopamine beta-hydroxylase mediated by toxic metabolites of disulfiram as the main responsible, but the exact mechanism remains unclear. The aim of this report was to describe the clinical and neuroimaging findings in an unusual case of acute encephalitis due to disulfiram toxicity associated to chronic intranasal consume.

CASE REPORT A chronic alcoholic who referred snorted use of a very high dose of disulfiram without simultaneous alcohol intake developed an acute encephalopathy with a rapidly progressive respiratory failure. A characteristic neuroimage finding consisting in extensive bilateral symmetric involvement of both pallidal nuclei was described. Recovery and neurologic improvement were slow. Two months after the intoxication, the patient still had slight intentional tremor and a scheduled magnetic resonance imaging. showed evolution of symmetrical areas of cytotoxic edema to necrosis. CONCLUSION. Disulfiram-induced neurotoxicity must be suspect during chronic therapy with disulfiram or after acute ingestion of high doses. Symptoms such as symmetric sensory and motor neuropathy, confusion, catatonia, parkinsonism, ataxia, choreoathetosis, seizures and encephalopathy should make us rule out this disorder. A brain imaging test should be performed in these patients since a characteristic involvement of both nuclei pallidus has been described, but it is not present in all patients.
KeywordsAlcoholismDisulfiramEncephalopathyIntoxicationNeurotoxicityNuclei pallidus infarction CategoriesNeuroimagenTrastornos metabólicos y tóxicos
FULL TEXT Artículo en español English version

Introduction


Disulfiram-induced encephalopathy is a rare complication that has been well described in adults. Although it usually occurs in acute intoxication with high doses of disulfiram, late onset encephalopathy has also been reported. Some authors propose the inhibition of dopamine beta-hydroxylase mediated by toxic metabolites of disulfiram as the main responsible, but the exact mechanism remains unclear [1-4]. The aim of this report was to describe the clinical and neuroimaging findings in an unusual case of acute encephalitis due to disulfiram toxicity associated to chronic intranasal consume.
 

Case report


A 48-years old male was transferred to our hospital from a psychiatric center with a three day history of drowsiness, cerebellar ataxia and dysarthric speech. He denied fever in the preceding month. He referred snorted use of escitalopram and clonazepam on the previous days as well as consumption of intranasal disulfiram (1-2 g per day with a maximum dose of 10 g per day two days ago) during the last two months intended for recreational purposes.

He had a past medical history of hypertension without treatment and paranoid schizophrenia that had led to three admissions due to acute crisis associated to treatment discontinuation. He was on olanzapine 10 mg/8 horas and paliperidone 100 mg intramuscular monthly for the schizophrenia, as well as clonazepam 0.5 mg/24 hours and escitalopram 15 mg/24 hours. He was also under treatment with disulfiram 250 mg per day orally for chronic alcoholism despite still having an active consumption pattern.

On examination at the emergency department, respiratory rate was 20 breaths/minute, oxygen saturation was 98% to room air, heart rate was 85 beats/minute, blood pressure was 177/100 mmHg and the temperature was 36.2 °C. The patient was stuporous and disoriented with a Glasgow coma scale of 13/15. Cardiovascular, respiratory and abdominal examinations were otherwise unremarkable. On neurological examination, hyporeactive miotic pupils, profuse blinking, marked dysarthria and unstable gait were noted. There were no clinical signs of raised intracranial pressure or meningeal irritation.

Laboratory clinical test results showed hyperchloremic metabolic acidosis (pH: 7.28; actual bicarbonate: 16.4 mmol/L), polyglobulia and macrocytosis. Renal function and hepatic profile were normal. No other findings of interest were found. Toxicological study was negative for ethanol, methanol and ethylene glycol. Urine toxicity screening by immunoassay was positive for benzodiazepines. Computed tomography revealed nonspecific mild symmetrical hypodensities of both nuclei pallidus and posterior arms of internal capsules, cerebral atrophy and chronic lacunar infarcts (Figure a).

 

Figure. Computed tomography axial sequence showing hypodensity in bilateral globus pallidus and posterior limb of internal capsule.; b) Brain T2-weighted magnetic resonance imaging showing a symmetrical enhancement of both nuclei pallidus and posterior limb of internal capsule; c) Diffusion sequence disclosing a blood-brain barrier disruption; d-e) Brain magnetic resonance imaging showing symmetrical areas of necrosis in both nuclei pallidus.






 

Suspecting the patient’s encephalopathy was related to a pharmacological intoxication (mainly benzodiazepine) without being able to rule out other diagnostic possibilities, he was admitted to the hospital ward. This first hypothesis was supported by the fact that it was a hypnotic-sedative syndrome in a patient who referred consumption of benzodiazepines and had a positive qualitative study in urine.

Diazepam, nordiazepam and clonazepam plasma levels were requested, all of which were in the therapeutic or infra-therapeutic range (72 ng/mL, 412 ng/mL and negative, respectively). An electroencephalogram showed a diffuse slow activity, without focal or epileptiform abnormalities. Cerebrospinal fluid examination showed mild hyperproteinorachia and all microbiological results were negative.

The anamnesis with the patient was difficult since he provided contradictory information. In this sense, the explanation for which clonazepam levels were negative is that it was not possible to guarantee that the patient had actually taken clonazepam. Given these plasma levels, it is more likely that he had not been taking it. Moreover, the fact that the plasma levels of diazepam and nordiazepam were positive was consistent with the credibility of the information provided by the patient. In retrospect, blisters of diazepam were found in the patient’s home. Therapeutic plasma levels do not rule out the possibility of adverse effects, but they make their severity and the clinical course followed by the patient less likely. Benzodiazepines probably contributed to the condition, but causality could not be attributed taking into account these plasma levels.

On the other hand, hyperchloremic acidemia with normal lactate levels in the clinical context of this patient led us to propose the diagnosis of a metabolic disorder, especially organic acidemia, a disorder of fatty acid beta-oxidation, or a disorder of the urea cycle. The systematic study in plasma and urine of fatty acids, acylcarnitines, acylglycines and carnitine was negative. Also, ammonium levels were normal and hypoketotic hypoglycemia was not found. The acidemia resolved in less than 24 hours without any specific measures, which made the hypothesis of a metabolic disorder highly unlikely. Furthermore, during initial stabilization, the patient had received loads of NaCl 0.9%, which could have contributed to acidemia.

Within the following 24 hours, he presented a progressive level of consciousness decrease, with the development of a rapidly progressive respiratory failure that required endotracheal intubation and mechanical ventilation and transfer to the Intensive Care Unit (ICU).

Respiratory examination and thorax X-ray were suggestive of aspiration pneumonia, and he was treated accordingly. To further study the encephalopathy, a magnetic resonance imaging of the brain was performed (Figure b-c). It revealed extensive bilateral heterogeneous hyperintense signal on fluid-attenuated inversion recovery (FLAIR) and T2 in both globus pallidus, posterior limb of internal capsule and putamen (Figure b). T1-weighted sequence showed hypointensity in the mentioned areas.

At this point, the case was reorientated as a disulfiram induced encephalopathy, because the radiologic pattern had been previously reported in the literature in other cases of disulfiram intoxication, as well as in carbon monoxide intoxication. The diagnosis of encephalopathy due to disulfiram was made by exclusion criteria. According to Naranjo et al [5] algorithm with a score of 4 out of 10, it was considered possible to attribute causality to disfulfiram in this case. In turn, the published cases of disulfiram encephalopathy present important similarities to the case. There are no reports with inhaled disulfiram since it is not an approved route of administration. Unfortunately, disulfiram plasma could not be performed.

The respiratory condition of the patient gradually improved during the next two weeks making progress in weaning until extubation. After sedatives withdrawal, difficulties of gaze supraversion, intentional tremor and dysmetria in the finger-nose maneuver as well as proximal weakness in upper and lower limbs were noticed on neurological examination. Subsequently, the patient showed neurologic improvement. The ocular motility limitation and weakness were resolved in a few days, but he persisted with mild intentional tremor and slight dysmetria. Due to critically illness myopathy, gait could not examinate until two weeks later, when a complete resolution of the ataxia was verified.

The patient was discharged with slight intentional tremor with a scheduled neuroimaging test in two months that showed evolution of symmetrical areas of cytotoxic edema to necrosis (Figure d-e).
 

Discussion


We report a case of late-onset acute encephalopathy associated to intranasal consume of disulfiram. We have not found previous reports of disulfiram bioavailability or intoxication following this administration route, although high levels have been found experimentally in animals [6]. In our patient the neurotoxicity appeared after many years of treatment, probably due to a massive inhaled intake. Moreover, history of schizophrenia may have contributed to susceptibility to these effects.


In conclusion, disulfiram-induced neurotoxicity must be suspected during chronic therapy with disulfiram or after acute ingestion of high doses, and not necessarily associated with alcohol intake. Symptoms such as symmetric sensory and motor neuropathy, confusion, catatonia, parkinsonism, ataxia, choreoathetosis, seizures and encephalopathy should make us rule out this disorder. A brain imaging test should be performed in these patients since a characteristic involvement of both nuclei pallidus has been described, but it is not present in all patients.

 

References
 


 1. Peddawad D, Nagendra S, Chatterjee R, Faldu H, Chheda A. Fulminant encephalopathy with unusual brain imaging in disulfiram toxicity. Neurology 2018; 90: 518-9.

 2. Boukriche Y, Weisser I, Aubert P, Masson C. MRI findings in a case of late onset disulfiram-induced neurotoxicity. J Neurol 2000; 247: 714-5.

 3. Zorzon M, Masè G, Biasutti E, Vitrani B, Cazzato G. Acute encephalopathy and polyneuropathy after disulfiram intoxication. Alcohol Alcohol 1995; 30: 629-31.

 4. Borrett D, Ashby P, Bilbao J, Carlen P. Reversible, late-onset disulfiram-induced neuropathy and encephalopathy. Ann Neurol 1985; 17: 396-9.

 5. Naranjo CA, Busto U, Abel JG, Sellers EM. Empirical delineation of the probability spectrum of adverse drug reactions. Clin Pharmacol Ther 1981; 29: 267-8.

 6. Qu Y, Sun X, Ma L, Li C, Xu Z, Ma W, et al. Therapeutic effect of disulfiram inclusion complex embedded in hydroxypropyl-β-cyclodextrin on intracranial glioma-bearing male rats via intranasal route. Eur J Pharm Sci 2021; 156: 105590.

 

Encefalopatía inducida por disulfiram intranasal: resultados clínicos y de neuroimagen


Introducción. La encefalopatía inducida por disulfiram es una complicación rara que se ha descrito en adultos, generalmente en intoxicaciones agudas, aunque también se ha comunicado en forma de encefalopatía de aparición tardía. Su mecanismo fisiopatológico se desconoce con exactitud, pero se atribuye a un posible papel en la inhibición de la dopamina beta-hidroxilasa mediada por metabolitos tóxicos del disulfiram. El objetivo de este trabajo fue describir los hallazgos clínicos y en la neuroimagen en un caso inusual de encefalopatía aguda tóxica inducida por un consumo intranasal crónico de disulfiram.

Caso clínico. Paciente de 48 años con enolismo crónico que refirió el uso inhalado por vía intranasal de una dosis muy elevada de disulfiram sin ingesta simultánea de alcohol desarrolló una encefalopatía aguda con insuficiencia respiratoria rápidamente progresiva. La neuroimagen reveló una extensa afectación simétrica bilateral de ambos núcleos pálidos, un hallazgo característico en esta intoxicación. La recuperación neurológica fue lenta. Dos meses después de la intoxicación, el paciente presentaba un ligero temblor intencional residual y una resonancia magnética mostró una evolución de las áreas simétricas de edema citotóxico a necrosis.

Conclusión. La neurotoxicidad inducida por disulfiram debe sospecharse durante el tratamiento crónico con disulfiram o después de una ingesta aguda de dosis elevadas. La presencia de síntomas como una neuropatía sensitivomotora simétrica, confusión, catatonía, parkinsonismo, ataxia, coreoatetosis, convulsiones y encefalopatía nos debe obligar a descartar este trastorno. La neuroimagen debe considerarse en este escenario, ya que se ha descrito una afectación característica de ambos núcleos pálidos.

Palabras clave. Alcoholismo. Disulfiram. Encefalopatía. Infarto del núcleo pálido. Intoxicación. Neurotoxicidad.
 

 

© 2022 Revista de Neurología

Si ya es un usuario registrado en Neurologia, introduzca sus datos de inicio de sesión.


Rellene los campos para registrarse en Neurologia.com y acceder a todos nuestros artículos de forma gratuita
Datos básicos
He leído y acepto la política de privacidad y el aviso legal
Seleccione la casilla si desea recibir el número quincenal de Revista de Neurología por correo electrónico. De forma quincenal se le mandará un correo con los títulos de los artículos publicados en Revista de Neurología.
Seleccione la casilla si desea recibir el boletín semanal de Revista de Neurología por correo electrónico. El boletín semanal es una selección de las noticias publicadas diariamente en Revista de Neurología.
Seleccione la casilla si desea recibir información general de neurologia.com (Entrevistas, nuevos cursos de formación, eventos, etc.)
Datos complementarios

Se os solicita los datos de redes para dar repercusión por estos medios a las publicaciones en las que usted participe.



Estimado usuario de Revista de Neurología,

Debido a la reciente fusión por absorción de VIGUERA EDITORES, S.L.U., la entidad gestora de las publicaciones de Viguera Editores, entre ellas, Revista de Neurología, por EVIDENZE HEALTH ESPAÑA, S.L.U., una de las sociedades también pertenecientes al Grupo Evidenze, y con la finalidad de que Usted pueda seguir disfrutando de los contenidos y distintos boletines a los que está suscrito en la página web de neurologia.com, es imprescindible que revise la nueva política de privacidad y nos confirme la autorización de la cesión de sus datos.

Lamentamos informarle que en caso de no disponer de su consentimiento, a partir del día 28 de octubre no podrá acceder a la web de neurologia.com

Para dar su consentimiento a seguir recibiendo la revista y los boletines de neurologia.com vía correo electrónico y confirmar la aceptación de la nueva política de privacidad, así como la cesión de sus datos a Evidenze Health España S.L.U., el resto de las entidades del Grupo Evidenze y sus partners y colaboradores comerciales, incluyendo la posibilidad de llevar a cabo transferencias internacionales a colaboradores extranjeros, pulse en el siguiente enlace:

ACEPTAR

Cancelar

Atentamente

El equipo de Revista de Neurología